X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PANACEA BIOTECH NATCO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 34.7 80.9 43.0% View Chart
P/BV x 17.7 1.8 984.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
NATCO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs877149 589.8%   
Low Rs42482 514.6%   
Sales per share (Unadj.) Rs223.484.1 265.5%  
Earnings per share (Unadj.) Rs31.1-18.3 -169.7%  
Cash flow per share (Unadj.) Rs40.3-6.7 -601.2%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.583.7 262.2%  
Shares outstanding (eoy) m33.0761.25 54.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.4 212.0%   
Avg P/E ratio x20.9-6.3 -331.7%  
P/CF ratio (eoy) x16.1-17.2 -93.6%  
Price / Book Value ratio x3.01.4 214.7%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5047,074 304.0%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m1,1281,449 77.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m7,3895,154 143.4%  
Other income Rs m167100 167.4%   
Total revenues Rs m7,5565,254 143.8%   
Gross profit Rs m1,793-766 -234.0%  
Depreciation Rs m304711 42.8%   
Interest Rs m3661,503 24.4%   
Profit before tax Rs m1,290-2,881 -44.8%   
Minority Interest Rs m4611 428.7%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m30917 1,837.5%   
Profit after tax Rs m1,027-1,121 -91.6%  
Gross profit margin %24.3-14.9 -163.2%  
Effective tax rate %23.9-0.6 -4,103.7%   
Net profit margin %13.9-21.8 -63.9%  
BALANCE SHEET DATA
Current assets Rs m3,6813,810 96.6%   
Current liabilities Rs m3,1238,365 37.3%   
Net working cap to sales %7.6-88.4 -8.6%  
Current ratio x1.20.5 258.8%  
Inventory Days Days89156 57.5%  
Debtors Days Days5967 87.3%  
Net fixed assets Rs m7,68514,480 53.1%   
Share capital Rs m33161 539.5%   
"Free" reserves Rs m6,670903 738.5%   
Net worth Rs m7,2595,127 141.6%   
Long term debt Rs m9555,832 16.4%   
Total assets Rs m11,95719,433 61.5%  
Interest coverage x4.5-0.9 -493.4%   
Debt to equity ratio x0.11.1 11.6%  
Sales to assets ratio x0.60.3 233.0%   
Return on assets %11.72.0 593.4%  
Return on equity %14.2-21.9 -64.7%  
Return on capital %20.73.6 569.9%  
Exports to sales %39.424.5 160.5%   
Imports to sales %5.710.2 56.0%   
Exports (fob) Rs m2,9081,264 230.1%   
Imports (cif) Rs m421525 80.3%   
Fx inflow Rs m3,4451,539 223.8%   
Fx outflow Rs m703942 74.6%   
Net fx Rs m2,743597 459.2%   
CASH FLOW
From Operations Rs m1,440599 240.4%  
From Investments Rs m-1,089-438 248.7%  
From Financial Activity Rs m-353-303 116.6%  
Net Cashflow Rs m-1-141 1.1%  

Share Holding

Indian Promoters % 52.0 74.5 69.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.6 1,306.7%  
FIIs % 16.6 1.3 1,279.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 23.6 110.2%  
Shareholders   25,395 10,259 247.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  AJANTA PHARMA  UNICHEM LAB  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - DR. DATSONS LABS COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS